Biopharmaceutical Company Secures European Patent for Dementia Treatment
BioXcel Therapeutics, Inc. (NASDAQ: BTAI), a pioneering biopharmaceutical company specializing in artificial intelligence-driven drug development, has made a substantial addition to its intellectual property (IP) portfolio. The contact Patent Office granted Patent No. 3,562,486 on March 13, 2024, which covers a multitude of sublingual dosage forms for BioXcel’s dexmedetomidine treatment targeting agitation in dementia patients….